on Parmantier & Cie. GmbH
PARMANTIER & CIE. Initiates Coverage of CLINUVEL Pharmaceuticals Ltd.
Frankfurt am Main, September 09, 2024 – Parmantier & Cie. GmbH has announced the commencement of coverage on CLINUVEL Pharmaceuticals Ltd., a biopharmaceutical company headquartered in Melbourne, Australia. Founded in 1987, CLINUVEL specializes in melanocortin-based therapies for skin pigmentation disorders and skin cancer prevention, with their flagship product SCENESSE® designed for erythropoietic protoporphyria (EPP).
In addition to its pharmaceutical division, CLINUVEL has developed a nutraceuticals division that focuses on nutritional supplements aimed at improving skin health. The company operates in two main sectors: pharmaceuticals and photocosmetics.
For further details, readers can access Parmantier & Cie's complete research report on CLINUVEL Pharmaceuticals Ltd. through Bloomberg or the company's website.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Parmantier & Cie. GmbH news